Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Amidst vaccine confusion, we must follow the evidence to protect against meningococcal disease
By Gary Puckrein, Ph.D. on behalf of Sanofi | Routine vaccination against IMD is essential to sustaining immunity during the years when young people are at greatest risk.
TL;DRAI
The CDC downgraded MenACWY and MenB vaccines from routine to risk-based recommendations, with 2024 recording 503 U.S. cases—the highest since 2013. Modeling projects 934 additional cases and 135 deaths by 2035 if the two-dose schedule is dropped.
1,327 words~6 min read
